[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200801447A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA200801447A1
EA200801447A1 EA200801447A EA200801447A EA200801447A1 EA 200801447 A1 EA200801447 A1 EA 200801447A1 EA 200801447 A EA200801447 A EA 200801447A EA 200801447 A EA200801447 A EA 200801447A EA 200801447 A1 EA200801447 A1 EA 200801447A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
products
hept
methylsulfonyl
pyrimidin
Prior art date
Application number
EA200801447A
Other languages
English (en)
Other versions
EA015682B1 (ru
Inventor
Миха Томаз Яклиц
Клемен Наверсник
Original Assignee
Лек Фармасьютиклз Д.Д.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лек Фармасьютиклз Д.Д. filed Critical Лек Фармасьютиклз Д.Д.
Publication of EA200801447A1 publication Critical patent/EA200801447A1/ru
Publication of EA015682B1 publication Critical patent/EA015682B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Химически стабильная композиция (Е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]пиримидин-5-ил]-(3R, 5S)-3,5-дигидрокси-гепт-6-еновой кислоты или ее фармацевтически приемлемой соли для перорального применения, такая как таблетки, капсулы, порошки, гранулы, была разработана с использованием стабилизирующих веществ, препятствующих образованию продуктов распада: лактона и продуктов окисления.
EA200801447A 2005-12-20 2006-12-18 Фармацевтическая композиция EA015682B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200500344 2005-12-20
PCT/EP2006/012180 WO2007071357A2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid

Publications (2)

Publication Number Publication Date
EA200801447A1 true EA200801447A1 (ru) 2008-12-30
EA015682B1 EA015682B1 (ru) 2011-10-31

Family

ID=37866173

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801447A EA015682B1 (ru) 2005-12-20 2006-12-18 Фармацевтическая композиция

Country Status (9)

Country Link
US (1) US20090093499A1 (ru)
EP (1) EP1968593B1 (ru)
JP (1) JP5235676B2 (ru)
CN (1) CN101330919B (ru)
AU (1) AU2006329006B2 (ru)
BR (1) BRPI0620629B8 (ru)
CA (1) CA2630704C (ru)
EA (1) EA015682B1 (ru)
WO (1) WO2007071357A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0706062A2 (pt) 2006-09-18 2011-03-22 Teva Pharma rosuvastatina cálcica cristalina
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
MXPA03008292A (es) * 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosificacion cronoterapeuticas que contienen glucocorticosteroides.
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN1886383A (zh) * 2003-10-22 2006-12-27 兰贝克赛实验室有限公司 无定形罗苏伐他汀钙的制备方法
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
DE602004032465D1 (de) * 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin

Also Published As

Publication number Publication date
CN101330919A (zh) 2008-12-24
BRPI0620629B1 (pt) 2020-01-14
CA2630704C (en) 2014-08-19
US20090093499A1 (en) 2009-04-09
AU2006329006B2 (en) 2013-02-28
BRPI0620629B8 (pt) 2021-05-25
CA2630704A1 (en) 2007-06-28
AU2006329006A1 (en) 2007-06-28
JP5235676B2 (ja) 2013-07-10
CN101330919B (zh) 2012-12-05
EP1968593A2 (en) 2008-09-17
EP1968593B1 (en) 2017-08-23
WO2007071357A2 (en) 2007-06-28
WO2007071357A3 (en) 2007-11-08
BRPI0620629A2 (pt) 2011-11-16
JP2009519985A (ja) 2009-05-21
EA015682B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
EA200801447A1 (ru) Фармацевтическая композиция
MY122707A (en) Pharmaceutical compositions
CY1110992T1 (el) ΣΥΝΔΥΑΣΜΕΝΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΠΕΡΙΕΧΟΥΝ (Ε)-7-[4-(4-ΦΘΟΡΟΦΑΙΝΥΛ)-6-ΙΣΟΠΡΟΠΥΛ-2-[ΜΕΘΥΛ(ΜΕΘΥΛΣΟΥΛΦΟΝΥΛ)ΑΜΙΝΟ]ΠΥΡΙΜΙΔΙΝ-5-ΥΛ](3r,5s)-3,5-ΔΙΥΔΡΟΞΥΕΠΤ-6-ΕΝΟΪΚΟ ΟΞΥ
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
TWI370817B (en) Novel crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[ methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt,and relevant manufacture process, pharmaceutical composition, and use
EA201100032A1 (ru) Соединения пиридина
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
RS51923B (en) SO 4 [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRILA
TW200744583A (en) Statin stabilizing dosage formulations
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
AR022462A1 (es) Uso de un agente que disminuye el colesterol
EA200970708A1 (ru) Фармацевтические композиции, включающие аторвастатин и никотиновую кислоту
TW201129557A (en) Pharmaceutical composition for oral administration
JP6750785B2 (ja) 安定なロスバスタチンカルシウム錠剤
NO20071720L (no) Fumarat av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril.
JP6573098B2 (ja) 安定なロスバスタチンカルシウム錠剤
UY30336A1 (es) Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma
TR200800269A2 (tr) Stabil farmasötik formülasyon ve hazırlama yöntemleri
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UY27271A1 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM